



Conversion of Convertible Notes & Cleansing Statement

NEW YORK and SYDNEY, Australia, December 21, 2021 - Beroni Group Limited (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an international diversified biopharmaceutical enterprise focused on the research, development, innovation and commercialization of therapies and products for treatment of global diseases, is pleased to announce that the holder of 28,986 convertible notes have elected to convert the convertible notes into fully paid ordinary shares in the Company. Each of the convertible notes has a face value of US\$100.

8,986 convertible notes are converting into 520,023 ordinary shares in the Company (for details of these convertible notes please refer to announcement dated 27 May 2020). The Company agreed to the extension of convertible notes and the issue of additional 5% shares if the notes are converted (refer to announcement dated 22 November 2021). As a result, an additional 26,001 ordinary shares will be issued to the noteholder.

The remaining 20,000 convertible notes are converting into 200,000 ordinary shares. For details of the 20,000 convertible notes please refer to announcement dated 28 May 2021.

Notice pursuant to Section 708A(5)(e) of the Corporations Act 2001

The Company gives notice pursuant to section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act) that:

1. The Company has issued a total of 746,024 ordinary shares;
2. The Company issued the shares without disclosure under Part 6D.2 of the Corporations Act;
3. The Company is providing this notice under section 708A(5)(e) of the Corporations Act;
4. As at the date of this notice, the Company has complied with:
 - i. The provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - ii. Section 674 of the Corporations Act; and
5. As at the date of this notice, other than as disclosed above, there is no information to be disclosed which is excluded information of the type referred to in Sections 708A(7) and 708A(8) of the Corporations Act.

About Beroni Group Limited

Beroni Group is an international biopharmaceutical enterprise dedicated to the innovation and commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases. Its diversified portfolio is comprised of FDA/CE approved virus diagnostic kits, an e-commerce platform for the sale of pharmaceutical products and a development pipeline targeting oncology and cell therapies. Beroni has operations in Australia, United States, China and Japan. It is listed on the National Stock Exchange of Australia and traded on the OTC markets in the USA. To learn more about Beroni, please visit www.beronigroup.com.

For further information, please contact us at:

Phone: +61 2 9159 1827

Email: enquiry@beronigroup.com

Website: www.beronigroup.com